Tag Archives: The Stem Cell Blog

Evolving a more versatile CRISPR-Cas9 – Phys.Org

Continue reading

2018-03-02 NEWS

Phys.Org

Evolving a more versatile CRISPR-Cas9
Phys.Org
SpCas9 crystal structure. Highlighted are the sgRNA (red), DNA strands (dark and light blue), and xCas9 mutations (orange, green, and magenta). Credit : Courtesy of the Liu lab. For all of Cas9’s potential in research and therapeutics, it—as well as
CRISPR enzyme can also cleave RNA, finds studyNews-Medical.net
New Enzyme Makes CRISPR More PowerfulThe Scientist
Broad Researchers Develop More Widely Compatible Cas9 VariantGenomeWeb

all 6 news articles »

Continue reading

2018-03-02 NEWS

Business Wire (press release)

MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate
Business Wire (press release)
LONDON & NEW YORK–(BUSINESS WIRE)–MeiraGTx, a London and New York based gene therapy company, announced today the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to MeiraGTx’s gene therapy product candidate A002 for

and more »

Continue reading

2018-03-02 NEWS

SelectScience

Editorial Article: 7 Steps to Better Gene Editing and CRISPR technology – Special Feature
SelectScience
In this editorial feature, we bring you the latest developments in gene editing and CRISPR technology. 02 Mar 2018. AddThis Sharing Buttons. Share to LinkedIn LinkedInShare to Facebook FacebookShare to Twitter TwitterShare to Email EmailShare to More
Crispr Therapeutics (CRSP) PT Raised to $51.00 at CitigroupThe Ledger Gazette
Analyst Views On Top Movers In Recent Trade: JRjr33, Inc. (JRJR), CRISPR Therapeutics AG (CRSP)Post Analyst
What Recent Ownership Trends Suggest About CRISPR Therapeutics AG (CRSP)’s Future PerformanceStockNewsGazette
The Lincolnian Online –registrarjournal.com –Kaplan Herald
all 12 news articles »
Continue reading

2018-03-02 NEWS

BioPharma-Reporter.com

Draper touts new bioprocessing method as ‘next big advance in CAR T-cell treatment’
BioPharma-Reporter.com
Viral vectors, the delivery vehicle of genomic materials into specific cells, can account for as much as 75% of a treatment’s cost, according to the company. “Second, the device removes the expense of additional touch labor and reduces the potential